Hypertension: Is it time to replace drugs with nutrition and nutraceuticals?

P and T

Volumn 39, Issue 4, 2014, Pages 291-295

  Alexander, Walter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARNITINE; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; EPLERENONE; HYDROCHLOROTHIAZIDE; ICOSAPENTAENOIC ACID; INTERLEUKIN 17; MAGNESIUM; NEBIVOLOL; NITRIC OXIDE; NUTRACEUTICAL; OMEGA 3 FATTY ACID; POTASSIUM; PYRIDOXINE; RESVERATROL; SPIRONOLACTONE; TAURINE; UNINDEXED DRUG;

BLOOD PRESSURE MONITORING; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; GENE EXPRESSION; HUMAN; HYPERTENSION; INFLAMMATION; INTERNAL MEDICINE; NOTE; NUTRITION; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84898884472     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (21)

1. Houston, MC. Nutrition and nutraceutical supplements for the treatment of hypertension. J Clin Hypertens (Greenwich) part I, 2013;15:752-757; part II, 2013;15:845-851; part 3, 2013;15:931-937.
2. Mayo Clinic. Diseases and Conditions: High blood pressure (hypertension). Available at: http://www.mayoclinic.org/diseasesconditions/ high-blood-pressure/basics/definition/con-20019580. Accessed March 7, 2014.
3. Tian N, Penman AD, Mawson AR, et al. Association between circulating specific leukocyte types and blood pressure: the Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Hypertens 2010;4(6):272-283.
4. Herrada AA, Campino C, Amador CA, et al. Aldosterone as a modulator of immunity: implications in the organ damage. J Hypertens 2011;29(9):1684-1692.
5. Harrap SB. Blood pressure genetics: time to focus. J Am Soc Hypertens 2009;3(4):231-237.
6. Sim JJ, Shi J, Calara F, et al. Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort. J Hypertens 2011:29(11):2226-2235.
7. Hillaert MA, Lentjes EG, Beygui F, et al. Measuring and targeting aldosterone and renin in atherosclerosis-a review of clinical data. Am Heart J 2011;162(4):585-596.
8. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113(9):1213-1225.
9. Bloch MJ, Basile JN. UK guidelines call for routine 24-hour ambulatory blood pressure monitoring in all patients to make the diagnosis of hypertension-not ready for prime time in the United States. J Clin Hypertens (Greenwich) 2011;13(12)871-872.
10. Morgan TO. The importance of sleep blood pressure. Expert Rev Cardiovasc Ther 2010;8(6):803-809.
11. Cuspidi C, Giudici V, Negri F, Sala C. Nocturnal nondipping and left ventricular hypertrophy in hypertension: an updated review. Expert Rev Cardiovasc Ther 2010;8(6):781-792.
12. Kaut O, Kovacs A, Okulla T, et al. Reversible multifocal leukoencephalopathy associated with a nocturnal blood pressure nondipper pattern. Blood Pressure 2010;19(4):267-269.
13. Xu T, Zhang YQ, Tan XR. The dilemma of nocturnal blood pressure. J Clin Hypertens (Greenwich) 2012;14(11):787-791.
14. Cuspidi D, Sala C, Valerio C, et al. Nocturnal blood pressure in untreated essential hypertensives. Blood Pressure 2011;20(6):335-341.
15. White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2001;57(3):413-420.
16. Acelajado MC, Pisoni R, Dudenbostel T, et al. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hyperten 2012;6(1):66-72.
17. Al Badarin FJ, Abuannadi MA, Lavie CJ, et al. Evidence-based diuretic therapy for improving cardiovascular prognosis in systemic hypertension. Am J Cardiology 2011;107(8):1178-1184.
18. Rosendorff C. Why are we still using hydrochlorothiazide? J Clin Hypertens (Greenwich) 2011;13(12):867-869.
19. Ambrosioni E, Veronesi M. Clinical role of Natrilix SR in the treatment of at-risk hypertensive patients. J Hypertens 2003;21(1):S13-17.
20. Houston MC. The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease. Ther Adv Cardiovasc Dis 2010;4:165-183.
21. McCabe-Sellers B, Frankel EH, Wolfe JJ, eds. Handbook of Food Drug Interactions. Boca Raton, Florida. CRC Press, 2003.